68 related articles for article (PubMed ID: 8442152)
1. Malignancies under cyclosporine after kidney transplantation: analysis of a 10-year period.
Frei U; Bode U; Repp H; Schindler R; Brunkhorst R; Vogt P; Hauss J; Pichlmayr R
Transplant Proc; 1993 Feb; 25(1 Pt 2):1394-6. PubMed ID: 8442152
[No Abstract] [Full Text] [Related]
2. Malignancy under immunosuppressive therapy including cyclosporine.
Ritters B; Grabensee B; Heering P
Transplant Proc; 1994 Oct; 26(5):2656-7. PubMed ID: 7940831
[No Abstract] [Full Text] [Related]
3. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients.
Hiesse C; Larue JR; Kriaa F; Blanchet P; Bellamy J; Benoit G; Charpentier B
Transplant Proc; 1995 Aug; 27(4):2450-1. PubMed ID: 7652877
[No Abstract] [Full Text] [Related]
4. Increasing transplant cancer patient survival by conversion of immunosuppressive agents.
Chuang FR; Hsieh H; Hsu KT; Huang HF
Transplant Proc; 1996 Jun; 28(3):1346-7. PubMed ID: 8658687
[No Abstract] [Full Text] [Related]
5. Influence of antilymphocyte globulin upon the incidence of malignancies after kidney transplantation.
Luciani J; Benalia H; Bitker MO; Mouquet C; Chartier-Kastler E; Ourhama S; Jacobs C; Chatelain C; Viars P
Transplant Proc; 1993 Jun; 25(3):2302. PubMed ID: 8516907
[No Abstract] [Full Text] [Related]
6. Cancer after transplantation in Catalonia.
Vilardell J; Oppenheimer F; Castelao AM; Puig JM; Cantarell MC; Solá R; Lauzurica R
Transplant Proc; 1992 Feb; 24(1):124. PubMed ID: 1539205
[No Abstract] [Full Text] [Related]
7. Incidence of noncutaneous malignancies in kidney transplant recipients: a 20-year follow-up.
Mouquet C; Benalia H; Ourahma S; Barrou B; Bitker MO; Luciani J; Chatelain C; Viars P
Transplant Proc; 1995 Apr; 27(2):1764. PubMed ID: 7725492
[No Abstract] [Full Text] [Related]
8. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation.
Ketel BL; Turton-Weeks S; Reed K; Barone GW
Transplant Proc; 1996 Apr; 28(2):899. PubMed ID: 8623453
[No Abstract] [Full Text] [Related]
9. Incidence of post kidney transplantation neoplasm in Thailand.
Jirasiritham S; Jirasiritham S; Sumethkul V; Chiewsilp P
Transplant Proc; 1996 Jun; 28(3):1586-7. PubMed ID: 8658795
[No Abstract] [Full Text] [Related]
10. Tumors after transplantation: are there associated factors?
Jacobs U; Paar D; Buszello H; Klehr HU
Transplant Proc; 1996 Dec; 28(6):3248. PubMed ID: 8962258
[No Abstract] [Full Text] [Related]
11. Acute vascular rejection with hemolytic uremic syndrome in kidneys from non-heart-beating donors: associated with secondary grafts and early cyclosporine treatment?
Schlumpf R; Candinas D; Weder W; Röthlin M; Zollinger A; Bleisch J; Retsch M; Largiadèr F
Transplant Proc; 1993 Feb; 25(1 Pt 2):1518-21. PubMed ID: 8442172
[No Abstract] [Full Text] [Related]
12. Incidence of de novo malignancies in renal transplant patients after anti-T-lymphocytic therapy.
Kosch M; Könecke J; Hausberg M; Kisters K
Clin Nephrol; 2001 Dec; 56(6):S35-6. PubMed ID: 11770811
[No Abstract] [Full Text] [Related]
13. Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival.
Terasaki PI; Cho Y; Takemoto S; Cecka M; Gjertson D
Transplant Proc; 1996 Jun; 28(3):1144-5. PubMed ID: 8658601
[TBL] [Abstract][Full Text] [Related]
14. Single-center experience with cyclosporine therapy for kidney transplantation: analysis of a twenty-year period in 1200 patients.
Snanoudj R; Kriaa F; Arzouk N; Beaudreuil S; Hiesse C; Durrbach A; Charpentier B
Transplant Proc; 2004 Mar; 36(2 Suppl):83S-88S. PubMed ID: 15041313
[TBL] [Abstract][Full Text] [Related]
15. The effect of cyclosporine A in cadaver donor retransplants: a surprising effect of the sex of the donor.
Cecka JM; Cicciarelli J; Terasaki PI
Transplant Proc; 1987 Feb; 19(1 Pt 3):1842-4. PubMed ID: 3274440
[No Abstract] [Full Text] [Related]
16. Drug-induced gingival overgrowth and class II major histocompatibility antigens.
Pernu HE; Knuuttila ML; Huttunen KR; Tiilikainen AS
Transplantation; 1994 Jun; 57(12):1811-3. PubMed ID: 8016888
[No Abstract] [Full Text] [Related]
17. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
Joss N; Rodger RS; McMillan MA; Junor BJ
Transplantation; 2007 Mar; 83(5):582-7. PubMed ID: 17353778
[TBL] [Abstract][Full Text] [Related]
18. Donor-specific transfusion for kidney transplantation in the cyclosporine era.
Inoue S; Aikawa M; Dobashi Y; Kuzuhara K; Yanagisawa T; Ootubo O; Mimura N
Transplant Proc; 1996 Jun; 28(3):1220-1. PubMed ID: 8658633
[No Abstract] [Full Text] [Related]
19. Malignancy following renal transplantation.
Sheil AG; Disney AP; Mathew TG; Amiss N; Excell L
Transplant Proc; 1992 Oct; 24(5):1946-7. PubMed ID: 1412921
[No Abstract] [Full Text] [Related]
20. Effect of hypertension, hyperlipidemia and cyclosporine A therapy on long-term renal allograft survival.
Maeda H; Sakamoto K; Kashiwabara H; Hachisu T; Yamada H; Matsushita K; Yamada K; Yokoyama T
Transplant Proc; 1996 Jun; 28(3):1633-4. PubMed ID: 8658816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
